Recruiting Cancer Clinical Trials

Destiny Gastric04 DS8201-A-U306

A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen
Description: This 2-arm trial will assess the effectiveness of trastuzumab deruxtecan v's Ramucirumab + Paclitaxel in patients with locally advanced, recurrent or metastatic gastric cancer or gastro-esophageal junction
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

Fortitude

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
Description: This double-blind trial assesses the effectiveness of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in patients Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

ZWI-ZW25 -301

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Description: This trial assesses the effectiveness of Zanidatamab plus Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Study Phase: Phase 3
Principal Investigator: Maeve Lowery
Further information